公司資料
Supernus 股價、新聞與催化劑
- 股票代碼:
- SUPN
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
45.85 USD (-3.37%)
收盤價
最後更新: 2026年8月21日
2.56B USD
市值
股價為何變動
As of Aug 21, 2026, SUPN closed down 3.37% at $45.85. No new same-company headline was identified in the current news window.
公司概覽
CNS Commercial Portfolio
Supernus Pharmaceuticals develops and commercializes treatments for central nervous system disorders. Its marketed portfolio spans attention-deficit hyperactivity disorder, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea.
Growth Products
The company’s principal growth brands include Qelbree for ADHD, GOCOVRI for dyskinesia in Parkinson’s disease, ONAPGO for continuous treatment of motor fluctuations in Parkinson’s disease and ZURZUVAE for postpartum depression. ZURZUVAE is commercialized through an economic collaboration with Biogen.
Epilepsy and Depression Pipeline
SPN-817 is a selective acetylcholinesterase inhibitor in a Phase 2b trial for treatment-resistant focal seizures. SPN-820 is designed to increase mTORC1-mediated synaptic function and is in Phase 2b development as an adjunctive treatment for major depressive disorder.
ADHD Pipeline Expansion
SPN-443 is a novel stimulant candidate for ADHD. Its planned first-in-human study extends Supernus’s pipeline within a therapeutic area where the company already has commercial infrastructure through Qelbree.
未來催化劑
- Phase 1 initiation for SPN-443 expected in the second half of 2026.
- FDA submission for a second ONAPGO supplier expected in the third quarter of 2026, with potential approval by mid-2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。